Mary E.R. O'Brien
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
Papers in
- Oncology 115
- Lung Cancer Research Studies 46
- Cancer Immunotherapy and Biomarkers 20
- Cancer Treatment and Pharmacology 11
- Colorectal Cancer Treatments and Studies 11
-
- Lung Cancer Treatments and Mutations 76
- Lung Cancer Diagnosis and Treatment 34
- Occupational and environmental lung diseases 25
- Co-authors
- Delvys Rodríguez‐Abreu (9 shared papers)Martin Reck (10 shared papers)Maya Gottfried (8 shared papers)Suman Rao (8 shared papers)Julie Renee Brahmer (8 shared papers)Rina Hui (8 shared papers)Nir Peled (8 shared papers)Katsuyuki Hotta (8 shared papers)
- Journals
- European Journal of Cancer (34 papers)Journal of Thoracic Oncology (30 papers)Lung Cancer (26 papers)Annals of Oncology (24 papers)British Journal of Cancer (16 papers)
- Partner nations
- United KingdomUnited StatesBelgium
In The Last Decade
Mary E.R. O'Brien
258 papers receiving 20.3k citations
Mary E.R. O'Brien's Hit Papers
Peers
Comparison fields: 5 of 182
- Oncology 11.3k
- Pulmonary and Respiratory Medicine 7.6k
- Cancer Research 1.9k
- Immunology 1.8k
- Pathology and Forensic Medicine 678
Countries citing papers authored by Mary E.R. O'Brien
This map shows the geographic impact of Mary E.R. O'Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary E.R. O'Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary E.R. O'Brien more than expected).
Fields of papers citing papers by Mary E.R. O'Brien
This network shows the impact of papers produced by Mary E.R. O'Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary E.R. O'Brien. The network helps show where Mary E.R. O'Brien may publish in the future.
Co-authors
The 25 scholars most cited alongside Mary E.R. O'Brien, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 262 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 8178 |
| 2 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% Hit paper breakdown → | 2021 | 802 |
| 3 | Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Hit paper breakdown → | 1997 | 729 |
| 4 | Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial Hit paper breakdown → | 2022 | 531 |
| 5 | 2006 | 500 | |
| 6 | 2017 | 429 | |
| 7 | 2004 | 377 | |
| 8 | Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial Hit paper breakdown → | 2015 | 361 |
| 9 | 2017 | 290 | |
| 10 | 1995 | 287 | |
| 11 | 2014 | 273 | |
| 12 | 2001 | 259 | |
| 13 | 2019 | 216 | |
| 14 | 2020 | 214 | |
| 15 | 2013 | 210 | |
| 16 | 2008 | 198 | |
| 17 | 1983 | 152 | |
| 18 | 2015 | 145 | |
| 19 | 2008 | 143 | |
| 20 | 2014 | 140 |
About Mary E.R. O'Brien
Mary E.R. O'Brien is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Epidemiology and Pathology and Forensic Medicine, having authored 262 papers that have together received 21.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (76 papers), Lung Cancer Research Studies (46 papers), Lung Cancer Diagnosis and Treatment (34 papers), Occupational and environmental lung diseases (25 papers), Cancer Immunotherapy and Biomarkers (20 papers), Cancer Genomics and Diagnostics (16 papers), Cancer Treatment and Pharmacology (11 papers) and Colorectal Cancer Treatments and Studies (11 papers). The work is most often cited by research in Oncology (11.3k citations), Pulmonary and Respiratory Medicine (7.6k citations), Cancer Research (1.9k citations), Immunology (1.8k citations) and Pathology and Forensic Medicine (678 citations). Mary E.R. O'Brien has collaborated with scholars based in United Kingdom, United States and Belgium. Frequent co-authors include Delvys Rodríguez‐Abreu, Martin Reck, Maya Gottfried, Suman Rao, Julie Renee Brahmer, Rina Hui, Nir Peled, Katsuyuki Hotta, Tibor Csőszi and Andrew George Robinson. Their work appears in journals such as European Journal of Cancer, Journal of Thoracic Oncology, Lung Cancer, Annals of Oncology and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.